Neurology

Top Medical News
Two-fold setback: ICU stay doubles dementia risk
Elvira Manzano, 14 hours ago
Intensive care unit (ICU) hospitalization doubles the risk of subsequent dementia in older adults, a longitudinal study suggests.
Global brain atrophy, white matter hypointensity tied to prefrailty
3 days ago
In otherwise cognitively healthy older adults, a prefrail state appears to be correlated with global brain atrophy and white matter hypointensity, a recent Japan study has found.
Soy isoflavones decrease frequency and duration of migraine attacks in women
Natalia Reoutova, 3 days ago

A randomized controlled trial of reproductive-age women prone to migraines has shown soy isoflavones supplementation to be effective at reducing the frequency and duration of migraine attacks.

Bilateral movement computer games improve upper limb recovery in stroke survivors
Natalia Reoutova, 3 days ago

A randomized controlled trial conducted by researchers from Hong Kong Metropolitan University, the Hong Kong Polytechnic University and the Chinese University of Hong Kong found greater improvements in upper limb sensorimotor functions among subacute stroke survivors who engaged in bilateral movement-based computer games (BMCG) vs conventional rehabilitation (CR) alone.


 

Novel polypill a potential first-line therapy for Parkinson’s disease
4 days ago
Treatment with angiotensin receptor blockers (ARBs) appears to reduce the risk of Parkinson’s disease (PD) in patients newly diagnosed with hypertension, reports a recent study.
Conjugated equine estrogen plus estradiol tied to increased risk of haemorrhagic stroke
4 days ago
Menopausal hormone therapy with conjugated equine estrogen appears to confer a heightened risk of developing haemorrhagic stroke among postmenopausal women as compared with the use of estradiol, as reported in a retrospective cohort study.
Special Reports
Product Highlight - Pontevia
16 Mar 2022
Galcanezumab Injection
Shifting paradigms in MS management: Early, optimized interventions improve patient outcomes
04 May 2018
Multiple sclerosis (MS) is one of the most common neurological disorders – affecting over 2.3 million people globally – and it is the leading cause of nontraumatic disability in young adults. However,the availability of supportive resources and services for people with MS is scarce in many regions of the world. In Malaysia, the prevalence of MS is estimated at 2-3/100,000; the current Malaysian clinical practice guidelines on the management of MS recommend disease modifying agents, such as interferon-β and teriflunomide, as first-line therapeutic agents. In this article, Dr Singer - in partnership with Sanofi and the Malaysian Society of Neurosciences - shares his insights into managing MS dynamically, highlighting the importance of early intervention in improving patient outcomes.
Conference Reports
MS patients on certain DMTs may have limited protection from COVID-19 vax
Roshini Claire Anthony, 30 May 2022

The overall rate of hospitalization for COVID-19 is low among patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs) who have been vaccinated against COVID-19, according to a prospective study from England. However, patients on ocrelizumab or fingolimod have elevated hospitalization rates.

Keto diet: Is there good evidence in MS?
Elvira Manzano, 23 May 2022
A diet rich in fat but low in carbohydrates, popularly known as the ketogenic or “keto” diet, offers clinical benefits to patients with relapsing multiple sclerosis (MS) in a phase II study. Quality of life (QoL) likewise improved, and so did disability.
Dogs catch yawns more easily from their owners than from strangers.
Tristan Manalac, 22 May 2022
Cognitive decline may be slower among older adults who have been long-time pet owners, reports a study presented at the recently concluded Annual Meeting of the American Academy of Neurology (AAN 2022).
Sustained benefits with ocrelizumab in relapsing-remitting MS
Roshini Claire Anthony, 19 May 2022

Patients with relapsing-remitting multiple sclerosis (RRMS) who have suboptimal response to disease-modifying therapies (DMTs) experienced low disease activity after switching to ocrelizumab, according to interim results of the LIBERTO study.

Reduced risk of psychosis relapse with continued pimavanserin use in patients with dementia
Elaine Soliven, 19 May 2022
Patients with Parkinson’s disease dementia (PDD) who continued treatment with pimavanserin had a lower risk of psychosis relapse compared with those on placebo, according to a post hoc analysis of the HARMONY* trial presented at AAN 2022.
No apparent link between COVID-19 vax and cerebrovascular outcomes
Roshini Claire Anthony, 13 May 2022

Several studies presented at AAN 2022 have revealed a lack of association between COVID-19 vaccination and negative cerebrovascular outcomes.

How does IV edaravone fare for ALS in the real world?
Audrey Abella, 10 May 2022
Intravenous (IV) edaravone seems to continue to provide hope for individuals with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease with no known cure, according to data presented at AAN 2022.
Product Highlights
CME Modules